Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for SRRK.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 253.78M
March 31, 2026 276.01M
December 31, 2025 245.49M
September 30, 2025 245.00M
June 30, 2025 233.29M
March 31, 2025 312.33M
December 31, 2024 368.63M
September 30, 2024 79.20M
June 30, 2024 133.62M
March 31, 2024 182.77M
December 31, 2023 225.22M
September 30, 2023 167.66M
June 30, 2023 202.50M
March 31, 2023 228.65M
December 31, 2022 260.24M
September 30, 2022 293.26M
June 30, 2022 329.51M
March 31, 2022 171.32M
Date Value
December 31, 2021 172.07M
September 30, 2021 187.26M
June 30, 2021 216.66M
March 31, 2021 240.54M
December 31, 2020 260.77M
September 30, 2020 62.98M
June 30, 2020 82.17M
March 31, 2020 98.65M
December 31, 2019 112.90M
September 30, 2019 121.79M
June 30, 2019 128.96M
March 31, 2019 97.52M
December 31, 2018 106.62M
September 30, 2018 102.34M
June 30, 2018 111.61M
March 31, 2018 47.30M
December 31, 2017 55.71M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Agenus, Inc. -199.08M
Amgen, Inc. 11.69B
Anika Therapeutics, Inc. 137.28M
BioCryst Pharmaceuticals, Inc. -454.29M
Imunon, Inc. 4.189M

Shareholders Equity (Quarterly) Related Metrics